Full-Time

Senior Engineer

Quality

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

Compensation Overview

€47k - €77k/yr

+ Bonus + Commission

Carrigtohill, Carrigtwohill, Co. Cork, Ireland

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Six Sigma
Word/Pages/Docs
Quality Assurance (QA)
Risk Management
Excel/Numbers/Sheets

Get referred to Stryker

See people who can refer or advise you

Requirements
  • Bachelor's degree in Science, Engineering, or an equivalent or related subject.
  • At least 2 years of work experience in a quality discipline.
  • Excellent English language skills, both oral and written.
  • Understanding of engineering and quality practices and methods.
  • High level of personal computer skills, including proficiency with Microsoft Word, Microsoft Excel, and Microsoft PowerPoint.
  • Working knowledge or experience with risk-based and statistical techniques, particularly process risk, statistical sampling plans, process capability, and gauge repeatability and reproducibility.
  • Ability to work as part of a multi-site team and travel as required.
Responsibilities
  • Provide quality engineering support and direction in quality assurance, quality control, and preventative activities within operations and other business functions, focusing on preventative measures and continuous improvement of products and processes.
  • Advocate and lead initiatives and projects to enhance quality performance within the business and ensure compliance with regulations and standards.
  • Work within the quality operations team with responsibility for quality-related activities under minimal supervision.
  • Work closely with operations and business functions to ensure quality performance of products and processes.
  • Provide oversight and approval of nonconformance and corrective and preventive action activities, and act as an activist and mentor in problem-solving and root-cause activities.
  • Lead and participate in the development and improvement of manufacturing processes for existing and new products.
  • Analyze and review concession requests.
  • Review and approve change-management activities.
  • Maintain key performance indicators for monitoring process quality, analyze and interpret trends, and take action as necessary.
  • Support the execution and analysis of quality assessment tests.
  • Advocate human-factor practices and apply human-factor identification and mitigation techniques.
  • Apply risk-management practices and tools, with high expertise in process risk, and provide input by identifying opportunities and weaknesses.
  • Optimize inspection methods and sampling, and support first-article inspections.
  • Apply statistical methods and techniques.
  • Participate in and interface with internal and external audits involving regulatory representatives, providing effective narratives and descriptions of areas of expertise.
  • Assist in the development and take responsibility for the review and approval of process and equipment validation and qualification.
  • Support manufacturing transfers to other plants or facilities and lead related quality activities.
  • Initiate, manage, and support shipment holds, product holds, and potential product escapes.
  • Coach and mentor others in quality topics and activities.
Desired Qualifications
  • Previous experience in a regulated environment.
  • Certified Quality Engineer certification or equivalent coursework or experience.
  • Understanding of medical-device manufacturing processes.
  • Familiarity with ISO 13485, Good Distribution Practice, and Good Manufacturing Practice.
  • Lean Six Sigma training.

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales grew 9%, driven by MedSurg, Neurotechnology, and Orthopaedics.
  • Mako posted record Q2 installations, and Mako RPS launched commercially in July 2026.
  • Pangea plated its first Europe case in London, while AVS closed in Q2 2026.

What critics are saying

  • March 2026 cyberattack still drives remediation costs and production disruption into Q3 2026.
  • Peripheral vascular backorders caused lost sales in Q2 2026 and normalize only by late Q3.
  • A repeat cyberattack shuts manufacturing and triggers hospital switching within weeks.

What makes Stryker unique

  • Mako Robotics passed 2.5 million procedures globally and operates in 47 countries.
  • Stryker bundles implants, capital equipment, and enabling technologies inside one hospital workflow.
  • Ortho Tech, launched April 2026, combines Mako, power tools, and instruments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 21st, 2026
Stryker holds steady despite cyber disruption as robotics drive 9% organic growth

Stryker started 2026 with strong underlying demand despite a cyber disruption. The medical technology company reported 9% organic sales growth in the second quarter, with MedSurg & Neurotechnology rising 9.2% and Orthopaedics up 8.6%. International sales grew 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako Robotics continues to drive growth, with more than 2.5 million procedures performed globally and systems installed across 47 countries. US knee sales increased 6.2% on continued Mako adoption. The company has a market capitalisation of $125.7 billion. Its bottom line is expected to improve 10.4% over the next five years. However, shares have fallen 6.7% this year, whilst the industry declined 15.2%.

Yahoo Finance
Aug 21st, 2026
Stryker wins $100M US Defense Logistics Agency contract modification

Stryker's Michigan sales unit secured a $100 million contract modification from the US Defense Logistics Agency, reinforcing its position as a key government healthcare supplier. The award complements Stryker's hospital and surgical product revenue, adding government-backed visibility. The company maintains its steady dividend track record, with a quarterly $0.88 per-share payout affirmed in August 2026. However, investors face ongoing concerns including regulatory friction, supply chain pressure, and pricing strain from government payers. Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029, requiring 8.9% yearly revenue growth. Fair value estimates from the Simply Wall St Community range from $331 to $426 per share. The contract highlights stable government contracting but does not fundamentally alter Stryker's near-term catalysts or main investment risks.

Yahoo Finance
Aug 2nd, 2026
Stryker shares drop 6.4% after Q2 earnings as analysts see 23% upside to $386.80 fair value

Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.

Yahoo Finance
Aug 1st, 2026
Stryker meets Q2 revenue expectations at $6.59B but supply chain woes dampen growth outlook

Stryker reported Q2 revenue of $6.59 billion, up 9.4% year on year, meeting Wall Street expectations. The medical technology company's non-GAAP earnings of $3.69 per share beat analyst estimates by 5.8%. Despite meeting forecasts, investors reacted negatively due to supply chain disruptions in the peripheral vascular business. Chief executive Kevin Lobo said the quarter focused on recovery from a recent cybersecurity incident, which caused production disruptions and elevated backlogs. The company expects backorders to normalise by the end of Q3. Management cited strong demand for capital equipment and Mako robotics, which saw record Q2 installations. Operating margin expanded to 25.2% from 18.5% last year, supported by operational discipline and efficiency initiatives. Management slightly raised full-year adjusted earnings guidance.

Yahoo Finance
Jul 31st, 2026
Stryker reports 9% organic sales growth in Q2 2026 despite cybersecurity impact

Stryker reported strong second-quarter 2026 results with 9% organic sales growth, driven by high single-digit gains in both its med surg and neurotechnology and orthopaedics businesses. The medical device company is recovering from a cybersecurity incident whilst ramping up production to meet demand. In the US, Stryker achieved 9% organic sales growth, with double-digit expansion in its medical, trauma extremities, and endoscopy divisions. The company's OrthoTech and instruments segments posted high single-digit growth. However, supply disruptions affected the peripheral vascular business, creating a significant backorder situation and lost sales. Stryker expects to resolve these issues by the end of the third quarter. The company also completed its acquisition of AVS during the quarter and remains confident in the long-term outlook for its peripheral vascular business.